FMTX
Forma Therapeutics Holdings, Inc.
Set alert
52-week range unavailable
- Open
- 20.00
- Prev close
- 20.01
- Mkt cap
- 1.01B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.98
- High
- 20.01
- Forward P/E
- -5.56
- Beta
- -0.95
- Short ratio
- 0.40
- Inst. own
- 91.07%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2022
- 50-d avg
- 17.92
- 200-d avg
- 10.90
- 1y target
- 21.00
Key statistics
- Market cap
- 1.01B
- Enterprise value
- 594.09M
- Trailing P/E
- 0.00
- Forward P/E
- -5.56
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.31
- EPS (TTM)
- -3.82
- Beta
- -0.95
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -106.88M
- Total cash
- 395.90M
- Total debt
- 32.55M
- Return on equity
- -38.27%
- Shares outstanding
- 47.86M
- Short % of float
- 3.31%
- 50-day average
- 17.92
- 200-day average
- 10.90
Analyst view
Consensus: buy
- Target (low)
- 20.00
- Target (mean)
- 21.00
- Target (high)
- 23.00
Next earnings
Nov 11, 2022
Expected Nov 11, 2022. Consensus EPS estimate -1.10.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2022 | Sep 1, 2022 | -1.08 | — | — | — |
| Aug 5, 2022 | Jun 1, 2022 | -0.97 | — | — | — |
| May 6, 2022 | Mar 1, 2022 | -1.04 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -0.94 | — | — | — |
| Nov 12, 2021 | Sep 1, 2021 | -0.96 | — | — | — |
| Aug 13, 2021 | Jun 1, 2021 | -0.79 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 2, 2022 | Credit Suisse | down | Outperform | Neutral |
| Sep 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 2, 2022 | Oppenheimer | down | Outperform | Perform |
| Sep 2, 2022 | Jefferies | down | Buy | Hold |
| May 27, 2022 | SVB Leerink | main | — | Outperform |
| Nov 12, 2021 | SVB Leerink | main | — | Outperform |
About Forma Therapeutics Holdings, Inc.
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed/refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. Forma Therapeutics Holdings, Inc. was founded in 2007 and is headquartered in Watertown, Massachusetts. As of October 14, 2022, Forma Therapeutics Holdings, Inc. operates as a subsidiary of Novo Nordisk A/S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- formatherapeutics.com
News
- Novo Nordisk announces the completion of the Forma Therapeutics acquisition
- FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMTX, FMTX, TRQ, SGFY
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IEA, CYBE, FMTX, TRQ
- Forma Therapeutics shares jump 50%; here is why
- FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX
- Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
- SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.
- Why Forma Therapeutics Holdings Stock Is On Fire Today
- Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Your note
Sign in to keep a note on FMTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLACKSON TIMOTHY P | Director | Stock Award(Grant) | Jun 7, 2022 | 30,840 |
| FANUCCI MARSHA H | Director | Stock Award(Grant) | Jun 7, 2022 | 59,782 |
| FREDERICK WAYNE A.I. M.D. | Director | Stock Award(Grant) | Jun 7, 2022 | 7,250 |
| KELLY PATRICK F | Officer | Conversion of Exercise of derivative security | Apr 7, 2022 | 104,884 |
| MELIAN AGUSTIN M.D. | Officer | Stock Award(Grant) | Jul 10, 2022 | 79,000 |
| MOLINA ARTURO | Director | Stock Award(Grant) | Jun 7, 2022 | 10,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 18.83% | 9,011,651 | 180.32M | Jun 29, 2022 |
| Armistice Capital, LLC | 9.90% | 4,736,000 | 94.77M | Jun 29, 2022 |
| Deep Track Capital, LP | 8.46% | 4,050,000 | 81.04M | Jun 29, 2022 |
| Cormorant Asset Management, LP | 6.63% | 3,172,204 | 63.48M | Jun 29, 2022 |
| Blackrock Inc. | 6.52% | 3,119,060 | 62.41M | Jun 29, 2022 |
| Baker Brothers Advisors, LLC | 4.23% | 2,024,876 | 40.52M | Jun 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.01% | 960,968 | 19.23M | Jun 29, 2022 |
| iShares Russell 2000 ETF | 1.65% | 787,789 | 15.76M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 0.91% | 435,980 | 8.72M | Jun 29, 2022 |
| iShares Russell 2000 Value ETF | 0.78% | 372,099 | 7.45M | Sep 29, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.66% | 314,652 | 6.30M | Sep 29, 2022 |
| Federated Hermes MDT Small Cap Core Fund | 0.60% | 286,165 | 5.73M | Jul 30, 2022 |